Trials / Active Not Recruiting
Active Not RecruitingNCT07431164
Augmented Reality-Based Aromatherapy Education for Older Adults With Early-Stage Dementia in Taiwan
The Impact of Augmented Reality-Based Aromatherapy Education on Symptoms in Older Adults With Early-Stage Dementia in Taiwan
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- National Taiwan Normal University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates an augmented reality (AR)-based aromatherapy education program designed for older adults with early-stage dementia in Taiwan. Participants are randomly assigned to either the intervention group, which receives AR-supported aromatherapy education sessions, or a comparison group receiving standard activities. The primary objective is to assess changes in neuropsychiatric symptoms and psychological well-being. Secondary outcomes include cognitive function and quality of life. The study aims to explore the feasibility and potential clinical benefits of integrating digital technology with non-pharmacological dementia care approaches.
Detailed description
The study includes multiple phases designed to examine both immediate and longer-term effects of the intervention. Phase 1 - Structured AR-Based Aromatherapy Education (Weeks 1-4): Participants receive the AR-based aromatherapy education program consisting of 12 structured sessions delivered over four weeks. Sessions integrate AR-guided instruction with hands-on aromatherapy learning activities. The Augmented Reality (AR)-Based Aromatherapy Education Module was systematically developed according to the 12 symptom domains of the Neuropsychiatric Inventory Questionnaire (NPI-Q). Each unit was designed to align a specific neuropsychiatric symptom with targeted plant-based aromatic stimulation, structured educational activities, and symptom-oriented behavioral goals. The intervention consisted of 12 structured units delivered over four to six consecutive weeks (two to three sessions per week). Each session integrated AR-based digital guidance with hands-on aromatherapy activities to provide multisensory stimulation, cognitive engagement, and structured emotional regulation support. Phase 2 - Aromatherapy Withdrawal Observation (Weeks 5-8): Following completion of the structured sessions, aromatherapy products are discontinued to observe potential maintenance or withdrawal effects of the intervention. Participants continue routine daily activities without additional aromatherapy sessions. Phase 3 - Personalized Aromatherapy Support (Weeks 9-12): Based on symptom profiles and individual preferences, participants may receive guidance on the use of personalized aromatherapy products intended to support symptom management in daily life. Phase 4 - Follow-Up Observation (Weeks 13-16): Participants are followed to evaluate the sustainability of intervention effects. Outcome assessments are conducted to examine longer-term changes in neuropsychiatric symptoms and related health outcomes. The comparison group receives routine care and standard daily activities at the care setting without participation in the AR-based aromatherapy education program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Augmented Reality-Based Aromatherapy Education Program | The augmented reality-based aromatherapy education module was developed using the Neuropsychiatric Symptom Checklist-Q (NPI-Q) framework to match specific neuropsychiatric symptoms with corresponding aromatherapy interventions. This intervention program was designed and refined by a multidisciplinary team of experts. The course comprises 12 units, completed over four consecutive weeks through 2-3 units per week. To ensure a systematic approach, each session integrates three units, allowing for comprehensive coverage of symptom clusters within a structured timeframe. Each symptom corresponds to a specific aromatherapy activity and its associated learning objectives. |
Timeline
- Start date
- 2025-05-23
- Primary completion
- 2025-10-30
- Completion
- 2026-03-01
- First posted
- 2026-02-24
- Last updated
- 2026-03-09
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT07431164. Inclusion in this directory is not an endorsement.